Hangzhou Innogate Pharma Co. Ltd. has identified kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer and viral infections.
Hangzhou Innogate Pharma Co. Ltd. has divulged new NLRP3 inflammasome inhibitors reported to be useful for the treatment of inflammation, cancer, infections and metabolic, respiratory, liver, kidney and autoimmune diseases, among other disorders.
